Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

GE Healthcare218 enrolled

Overview

Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

218

Conditions

Healthy

Interventions

[18F] FlutemetamolDRUG

Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The subject age is 18 to 40 years. * The subject has no evidence of thinking or memory problems by medical history. * The subject has a normal MRI scan. * The subject's general health is adequate to comply with study procedures. * The subject is willing and able to participate in all study procedures. Exclusion Criteria: * The subject has received any medical ionizing radiation exposure in the last 12 months (except planar x-ray or head CT). * The subject has a contraindication for (cannot undergo) MRI. * The subject has a history of head injury with loss of consciousness. * The subject has any significant medical, psychiatric or neurological condition that might be associated with brain pathology. * The subject has a family history of Alzheimer's Disease (AD); more than 1 first-degree relative.

Locations (1)

GE Healthcare

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid

The visual assessment of Flutemetamol PET image was performed by independent readers trained in the evaluation of PET brain amyloid imaging. The measure would consisted of the number of brain scans with amyloid (abnormal reading) or without amyloid (normal reading).

Time frame: PET scans performed on patients 90 minutes post Flutemetmol Administration

Secondary Outcomes

Measurement of Amyloid Content in Different Parts of the Brain

Is the computerized measurement of amyloid content in different parts of the brain. The Standard Uptake Value Ratio (SUVR) is defined as an average of frontal, anterior cingulate, pariteal, lateral-temporal and posterior cingulate / precuneous uptake following administration of Flutemetamol F18 Injection. The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.

Time frame: PET scans performed on patients 90 minutes post Flutemetmol Administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.